ASH 2015 Complete Coverage
Idelalisib in combination with bendamustine and rituximab is superior to bendamustine and rituximab alone.
In "ultra-high risk" patients with chronic lymphocytic leukemia (CLL), treatment with venetoclax monotherapy resulted in a high overall response rate.
Results of a phase 3 randomized trial support high intensity conditioning prior to allogeneic stem cell transplantation as standard of care.
The first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA) has shown strong anti-myeloma activity.
Minimal residual response (MRD) induced by blinatumomab montherapy was associated with longer survival and duration of response.
Adding ixazomib to lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma increased progression-free survival.
Ibrutinib is superior to temsirolimus for progression-free survival in patients with relapsed/refractory mantle cell lymphoma (MCL).
Combination of brentuximab vedotin with bendamustin is effective in Hodgkin lymphoma and anaplastic large T-cell lymphoma (ALCL).
For prognosis of long-term outcomes in chronic myeloid leukemia (CML), the European Treatment and Outcomes Study (EUTOS) score is recommended.
Obinutuzumab monotherapy for 1 cycle followed by venetoclax and obinutuzumab in elderly patients with chronic lymphocytic leukemia (CLL).
brutinib monotherapy was superior to chlorambucil with regard to survival and hematologic improvement.
Thromboprophylaxis with dalteparin is associated with a non-significant decreased risk of venous thromboembolism (VTE).
KPT-8602 allows a prolonged frequent dosing schedule in animal models of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Combination therapy of venetoclax with decitabine or azacitidine demonstrated tolerable safety in acute myeloid leukemia (AML).
Genetic and pharmacologic evidence point to splicing factor mutant leukemias as being "preferentially sensitive to splicing modulation in vivo."
Adding rituximab to the pediatric-inspired GRAALL protocol improved event-free survival in acute lymphoblastic leukemia.
The addition of midostaurin to standard chemotherapy significantly improved survival in acute myeloid leukemia (AML).
Single-agent clofarabine is inferior to standard therapy in older patients with newly diagnosed acute myeloid leukemia (AML).
Research has confirmed "the importance of genetically defined PD-1 mediated immune evasion in classical Hodgkin lymphomas."
Researchers have confirmed 2 clinically relevant minimal residual disease checkpoints in younger patients with acute myeloid leukemia (AML).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments
- ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer
- Bladder Cancer: Immunotherapies, Combination Therapies, and Current Research
- Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity
- Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma